Clinical trialNCT01263899CompletedPhase 2Interventional

A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies

SponsorS*BIOEnrollment28Hodgkin LymphomaIndolent LymphomaMantle Cell Lymphoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 2 study to assess the efficacy of SB1518 in the treatment of patients with advanced lymphoid malignancies including Hodgkin Lymphoma, Mantle Cell Lymphoma and Indolent Lymphoma (follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma and small lymphocytic lymphoma).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Anas Younes, MD
MD Anderson Cancer Center at University of Texas, Houston
Principal Investigator
clinicaltrials.gov ↗
Jonathan Friedberg, MD
University of Rochester James P. Wilmot Cancer Center
Principal Investigator
clinicaltrials.gov ↗
Julie Vose, MD
University of Nebraska
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Peter Martin, MD
Weill Medical College of Cornell University
Principal Investigator
clinicaltrials.gov ↗
Richard Klasa, MD
British Columbia Cancer Center - Vancouver Centre
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

University of British Columbia
Vancouver, British Columbia, Canada

United States

University of Nebraska Medical Center
Omaha, Nebraska, United States
Weill Medical College of Cornell
New York, New York, United States
University of Rochester James P. Wilmot Cancer Center
Rochester, New York, United States
Md Anderson Cancer Canter
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Pacritinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Dec 2010
Primary completion: 29 Feb 2012
Completion: 29 Feb 2012
Last update posted: 20 Apr 2012
Registered enrollment: 28
Registry id: NCT01263899

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.